Market Monitor chemicals Italy 2018

Market Monitor

  • Italia
  • Kjemikalier/Farmasøytisk

19 juli 2018

Further growth expected, but businesses dependent on construction, construction materials and consumer durables still require particular attention.

  • Expectations for 2018 are positive for now
  • Payments take 60 days on average
  • Non-payment issues in the oil/fuel wholesalers segment

Italy chemicals 2018 pic1

Italian chemicals production increased 3.5%, to EUR 55 billion in 2017. Exports, which accounted for 55% of total revenues, grew 9%. Domestic demand increased and expanded across all customer segments, except for construction and consumer durables. The fine chemicals and specialties segments grew 12.7% and 7.8% respectively.

Italy chemicals 2018 pic2

The outlook for 2018 remains positive for the time being, despite a slowdown in early 2018 (in Q1 of 2018 Italian chemicals production grew just 1.5%, below the European average of 1.9% and Italian manufacturing average growth of 4.6%). This slowdown was mainly due to increased domestic and international political uncertainty, impeding higher chemicals purchases.

Production of the pharmaceuticals industry amounted to EUR 30 billion in 2017, with foreign-owned pharmaceuticals producers accounting for 61% of total revenues. Exports accounted for 75% of total revenues, while at the same time public expenditure for pharmaceuticals in Italy is among the lowest in Europe and decreasing further.

On average, payments in the Italian chemicals/pharmaceuticals sector take around 60 days. Payment experience is good, and the level of protracted payments has been low over the past couple of years. The level of payment delays and insolvencies is low, and this should remain generally unchanged in H2 of 2018.

Italy chemicals 2018 pic3

However, we expect non-payments to increase in the oil/fuel wholesalers segment, affected by low profitability due to heavy taxation (VAT amounts to 22% and, together with other excises on fuels, the fiscal burden amounts to 64% of the final sales price of fuels) and international competition. Fiscal crimes (i.e. import of fuel from illegal markets to avoid VAT payments) have increased, while public authorities have started to investigate. In some cases, the bank accounts of companies involved in these crimes have been blocked.

Considering the generally positive outlook for the industry, the low level of bank bad debts and the above-average solvency of many businesses, our underwriting approach to the Italian chemicals/pharmaceuticals sector remains relaxed. However, subsectors and businesses dependent on construction, construction materials and consumer durables still require particular attention. At the same time, any increase in insecurity over the domestic and international economic situation and trade policies remains a downside risk.

Italy chemicals 2018 pic4

Compared to producers, chemicals/pharmaceuticals wholesalers generally show lower solvency and higher gearing ratios to finance their working capital needs. Due to the issues mentioned above a more cautious underwriting approach applies to wholesalers of fuel products. Wholesalers and retailers of pharmaceuticals, which are dependent on public healthcare expenditure and suffer from long payment duration by public entities and decreased margins, also remain in focus.

 

 

 

Relaterte dokumenter

Ansvarsfraskrivelse

Fremstillingene som er gitt her er kun generell informasjon, og skal ikke stoles på eller brukes som grunnlag for noe formål. Vennligst referer til selve polisen eller den aktuelle produkt- eller serviceavtalen for de styrende vilkårene. Ingenting i dette dokumentet skal tolkes til å skape noen rett, plikt eller ansvar fra Atradius' side, inkludert noen forpliktelse til å gjennomføre tilbørlig aktsomhet (due diligence) for kjøpere eller på dine vegne. Hvis Atradius gjennomfører tilbørlig aktsomhet for en kjøper, er det for egne underwriting-formål, og ikke til fordel for den forsikrede eller noen annen. I tillegg skal Atradius og tilhørende og tilknyttede selskaper og datterselskaper ikke i noe fall være ansvarlig for noen direkte, indirekte, spesielle eller tilfeldige skader eller følgeskader som følge av bruk av de fremstillinger som det er gitt informasjon om her.